Leerink Partnrs Comments on Disc Medicine Q1 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Disc Medicine in a report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($1.01) per share for the quarter. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Leerink Partnrs also issued estimates for Disc Medicine’s Q2 2025 earnings at ($1.16) EPS and Q3 2025 earnings at ($1.44) EPS.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.08.

Several other equities research analysts have also recently commented on the company. Scotiabank raised their target price on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday. Stifel Nicolaus increased their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a research note on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research note on Tuesday, January 21st. Finally, Wedbush reissued an “outperform” rating and issued a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $89.10.

Disc Medicine Stock Down 3.3 %

IRON opened at $54.33 on Monday. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60. The company has a fifty day moving average of $57.89 and a 200-day moving average of $55.70. The stock has a market cap of $1.62 billion, a PE ratio of -13.65 and a beta of 0.73.

Insiders Place Their Bets

In related news, COO Jonathan Yen-Wen Yu sold 1,610 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $87,873.80. Following the completion of the sale, the chief operating officer now owns 40,555 shares in the company, valued at approximately $2,213,491.90. This trade represents a 3.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Pamela Stephenson sold 3,137 shares of Disc Medicine stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $171,217.46. Following the completion of the sale, the insider now directly owns 69,529 shares in the company, valued at approximately $3,794,892.82. This represents a 4.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 74,080 shares of company stock valued at $4,523,520. Corporate insiders own 4.24% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors have recently added to or reduced their stakes in IRON. FMR LLC raised its position in shares of Disc Medicine by 358.7% in the fourth quarter. FMR LLC now owns 1,866,248 shares of the company’s stock valued at $118,320,000 after purchasing an additional 1,459,434 shares during the period. Wellington Management Group LLP grew its position in shares of Disc Medicine by 4.8% in the third quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock valued at $90,429,000 after purchasing an additional 83,731 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Disc Medicine by 23.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock valued at $88,421,000 after purchasing an additional 262,690 shares during the period. Janus Henderson Group PLC lifted its holdings in Disc Medicine by 62.4% during the 4th quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after purchasing an additional 467,988 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Disc Medicine by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 1,068,246 shares of the company’s stock worth $67,727,000 after purchasing an additional 18,716 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.